Literature DB >> 8326337

Decreased vitamin B12 and folate levels in cerebrospinal fluid and serum of multiple sclerosis patients after high-dose intravenous methylprednisolone.

S T Frequin1, R A Wevers, M Braam, F Barkhof, O R Hommes.   

Abstract

Twenty-one patients (15 women, 6 men) with definite multiple sclerosis (MS) were treated with 1000 mg intravenous methylprednisolone-succinate (MP) daily for 10 days. Before MP treatment there was a negative correlation (r = 0.59, P = 0.0084) between serum vitamin B12 and progression rate, defined as the ratio of the score on Kurtzke's Expanded Disability Status Scale and disease duration. A significant decrease was demonstrated in the cerebrospinal fluid (CSF) and serum levels of folate and in the CSF level of vitamin B12 after MP treatment. The decrease in serum B12 was not statistically significant. After MP treatment all median levels of vitamin B12 and folate were below the reference medians. We hypothesize that low or reduced vitamin B12/folate levels found in MS patients may be related to previous corticosteroid treatments. Otherwise a more causal relationship between low vitamin B12/folate and MS cannot be excluded. Further studies may be required to clarify the vitamin B12 and folate metabolism in patients with MS.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8326337     DOI: 10.1007/bf00838168

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  13 in total

1.  Quantitative MRI changes in gadolinium-DTPA enhancement after high-dose intravenous methylprednisolone in multiple sclerosis.

Authors:  F Barkhof; O R Hommes; P Scheltens; J Valk
Journal:  Neurology       Date:  1991-08       Impact factor: 9.910

2.  Multiple sclerosis and macrocytosis.

Authors:  R F Crellin; T Bottiglieri; E H Reynolds
Journal:  Acta Neurol Scand       Date:  1990-05       Impact factor: 3.209

Review 3.  Effects of high-to-mega-dose synthetic corticosteroids on multiple sclerosis patients with special reference to cerebrospinal fluid antibodies to myelin basic protein.

Authors:  K G Warren; I Catz; D J Carroll
Journal:  Clin Neuropharmacol       Date:  1987-10       Impact factor: 1.592

4.  Pathogenesis of subacute combined degeneration: a result of methyl group deficiency.

Authors:  J M Scott; J J Dinn; P Wilson; D G Weir
Journal:  Lancet       Date:  1981-08-15       Impact factor: 79.321

5.  New diagnostic criteria for multiple sclerosis: guidelines for research protocols.

Authors:  C M Poser; D W Paty; L Scheinberg; W I McDonald; F A Davis; G C Ebers; K P Johnson; W A Sibley; D H Silberberg; W W Tourtellotte
Journal:  Ann Neurol       Date:  1983-03       Impact factor: 10.422

6.  Vitamin B12 and folate concentrations in serum and cerebrospinal fluid of neurological patients with special reference to multiple sclerosis and dementia.

Authors:  T Q Nijst; R A Wevers; H C Schoonderwaldt; O R Hommes; A F de Haan
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-11       Impact factor: 10.154

7.  High-dose intravenous methylprednisolone in the treatment of multiple sclerosis: clinical-immunologic correlations.

Authors:  L Durelli; D Cocito; A Riccio; C Barile; B Bergamasco; G F Baggio; F Perla; M Delsedime; G Gusmaroli; L Bergamini
Journal:  Neurology       Date:  1986-02       Impact factor: 9.910

8.  Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS).

Authors:  J F Kurtzke
Journal:  Neurology       Date:  1983-11       Impact factor: 9.910

9.  The effect of high-dose steroids on MRI gadolinium enhancement in acute demyelinating lesions.

Authors:  J A Burnham; R R Wright; J Dreisbach; R S Murray
Journal:  Neurology       Date:  1991-09       Impact factor: 9.910

10.  Central-nervous-system methyl-group metabolism in children with neurological complications of HIV infection.

Authors:  R Surtees; K Hyland; I Smith
Journal:  Lancet       Date:  1990-03-17       Impact factor: 79.321

View more
  2 in total

1.  Iron and the folate-vitamin B12-methylation pathway in multiple sclerosis.

Authors:  S J van Rensburg; M J Kotze; D Hon; P Haug; J Kuyler; M Hendricks; J Botha; F C V Potocnik; T Matsha; R T Erasmus
Journal:  Metab Brain Dis       Date:  2006-05-26       Impact factor: 3.584

Review 2.  [Diet and multiple sclerosis].

Authors:  S Schwarz; H Leweling
Journal:  Nervenarzt       Date:  2005-02       Impact factor: 1.214

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.